Start of mandatory additional acceptance period for Biotest tender offer
Munich, 21 June 2017 - Tiancheng (Germany) Pharmaceutical Holdings AG, a company indirectly controlled by Creat Group Corporation, ("Bidder"), announced the start of the mandatory additional acceptance period for its voluntary takeover offer for all outstanding shares in Biotest AG ("Biotest"). After the required minimum acceptance threshold of at least 75% of all Biotest ordinary shares has been crossed, the additional acceptance period provides all remaining shareholders of Biotest with the opportunity to tender their shares and realize an attractive valuation.
As outlined in the offer document, the Bidder offers Biotest shareholders EUR28.50 per Biotest ordinary share and EUR19.00 per Biotest preference share in cash. The offer has been strongly and repeatedly recommended by the Biotest Management and Supervisory Board.
Mr Wu Xu, CEO of Creat, said: "With more than 75% of Biotest ordinary shares having been tendered, we have reached an important milestone. We are encouraged by the large majority of Biotest ordinary shareholders who have already seized this unique opportunity and accepted our offer. To help secure Biotest's long-term future, we invite all remaining ordinary and preference shareholders to accept the offer in the additional acceptance period in line with the Biotest Management and Supervisory Boards' recommendation."
Shareholders who have not yet accepted the offer can still tender their shares to the Bidder at unchanged terms until the end of the additional acceptance period on 4 July 2017 at 24:00 hrs (Frankfurt am Main local time)/18:00 hrs (New York local time).
The offer document as well as a presentation summarizing the key points of the offer are available at http://www.tiancheng-germany-pharmaceutical-angebot.de.
The completion of the takeover offer remains subject to foreign investment control and merger control approvals. Merger control approval in the United States has already been granted.
About Creat Group Corporation
Creat Group Corporation (www.creatgroup.com) is a leading Chinese investment group founded in 1992 that has significant expertise in the plasma industry. It invests in healthcare and pharmaceuticals, manufacturing, energy, finance, and natural resources. The company is based in Beijing, China, with other offices in Hong Kong and Shanghai. Through its investment in China's largest listed blood products company Shanghai RAAS as well as the 2016 acquisition of UK-based plasma supplier and manufacturer of plasma-derived protein therapeutics Bio Products Laboratory, Creat is a significant investor in the global plasma market.
This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Biotest. The definite terms and conditions of the takeover offer, as well as further provisions concerning the takeover offer, have been published in the offer document following approval by the German Federal Financial Supervisory Authority. Investors and holders of shares in Biotest are strongly advised to read the offer document and all other relevant documents regarding the takeover offer, since they contain important information.
The takeover offer has been issued exclusively under the laws of the Federal Republic of Germany and certain applicable provisions of U.S. securities law. Any contract that is concluded on the basis of the takeover offer is exclusively governed by the laws of the Federal Republic of Germany and is to be interpreted in accordance with such laws.
CNC - Communications & Network Consulting AG
T +49 69 506 037 570
21.06.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de